Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
11/11/25 Altimmune (ALT) pemvidutide for Non-Alcoholic Steatohepatitis (NASH) Subscribers Only Subscribers Only Subscribers Only
11/10/25 InflaRx (IFRX) INF904 for Hidradenitis Suppurativa Subscribers Only Subscribers Only Subscribers Only
11/10/25 Novo Nordisk (NVO) coramitug for Transthyretin Amyloid Cardiomyopathy (ATTR-CM, Wild Type Or Hereditary) Subscribers Only Subscribers Only Subscribers Only
11/10/25 Roche (RO) RG7845 for Multiple Sclerosis (MS) Subscribers Only Subscribers Only Subscribers Only
11/10/25 Roche (RO) RG7845 for Multiple Sclerosis (MS) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
01/31/2025 Subscribers Only Subscribers Only Trial Announcement - Initiation
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update